Experience of treatment of lung cancer patients using paclitaxel and carboplatin (Medical Journal of Indonesia, 2000)
Abstrak Sembilan belas pasien kanker paru jenis karsinoma bukan set kecil stage Jll & JV mendapat kemoterapi dengan paduan paklitaksel dan karboplatin di Rumah Sakit Kanker Dharmais dan Rumah Sakit Pusat Pertamina Jakarta, terdiri dari J4 laki-laki dan 5 perempuan. Diagnosis histologis ialah adenokarsinoma pada 13 pasien, karsinoma skuamosa pada 4 pasien dan karsinoma adenoskuamosa pada J pasien. Empat belas pasien termasuk stage JV, stage llJB terlihat pada 4 pasien dan stage 11/A pada 1 pasien. Paduan obat terdiri dari paklitaksel, dengan dosis 135-200 mg/m2 dan karboplatin 300 mg/m2 atau AUC 6 mg/ml.min, diberikan melalui infus setiap 3 minggu, paling sedikit 3 siklus. Pasien diikuti secara teratur sampai meninggal. Respon objektif berupa respon parsial (partial response) terlihat pada 12 pasien (63%), 2 pasien tidak menunjukkan perubahan (stable disease) dan perburukan terlihat pada 5 orang (26%). Dua pasien masih hidup masing-masing 22 dan 23 bulan setelah kemoterapi dimulai. Masa tahan hidup 1 tahun adalah 58%dan masa tengah tahan hidup ialah 14 bulan. Abstract Nineteen patients with stage 111 & IV nonsmall cell lung cancer were treated with regimen containing paclitaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina General Hospital, Jakarta - Indonesia. There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquamous carcinoma in J patient. Fourteen patients were in stage IV, 4 had stage 11/B, one had stage fl/A disease. The regimen contains paclitaxel 135-200 mg/m2, combined with carboplatin 300 mg/m2 or AUC 6 mg/ml. min, given every 3 weeks. Those who undenvent at least 3 cycles of chemotherapy were followed up until death. Objective improvement (partial response) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%). Two patients are still alive at 22 months and 23 months after starting chemotherapy. The one year survival rate was 58%and median survival time was 14 months. Keywords: nonsmall cell carcinoma, chemotherapy, paclitaxel, carboplatin The treatment